Optimal Scheduling of Anticipated COVID-19 Vaccination: A
Case Study of New York State
Syed Irfan Ali Meerzaâˆ—, Seyed M. Karimiâ€ , Bert B. Littleâ€¡,
Jacek M. ZuradaÂ§, Tamer InancÂ¶

arXiv:2008.10702v1 [q-bio.PE] 24 Aug 2020

July, 2020

Abstract
This study aims to determine an optimal control strategy for vaccine scheduling in COVID-19 pandemic
treatment by converting widely acknowledged infectious disease model named SEIR into an optimal control
problem. The problem is augmented by adding medication and vaccine limitations to match real-world situations.
Two version of the problem is formulated to minimize the number of infected individuals at the same provide the
optimal vaccine possible to reduce the susceptible population to a considerably lower state. Optimal control
problems are solved using RBF-Galerkin method. These problems are tested with a benchmarking dataset to
determine required parameters. After this step, problems are tested with recent data for New York State, USA.
The results regarding the proposed optimal control problem provides a set of evidences from which an optimal
strategy for vaccine scheduling can be chosen, when the vaccine for COVID-19 will be available.
Keywordsâ€” COVID-19, Coronavirus, SEIR, RBF-Galerkin method, Optimal control, Vaccination

1

Introduction

From the starting of the year 2020, the world faced a great challenge of the coronavirus outbreak. It started in December 2019
when there was a sudden increase of pneumonia of unknown etiology reported in Wuhan city, Hubei Province, China [1] [2]. A
scientific team of the Chinese Academy of Engineering announced that a new coronavirus has caused this outbreak. This new
coronavirus was named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses (ICTV) for its similarities
with the virus SARS-CoV found in 2003 [3]. This new virus causes acute respiratory illness and even fatal acute respiratory distress syndrome (ARDS). The diseases associated with SARS-CoV-2 was named COVID-19 by the World Health Organization
(WHO) [4]. The virus spread rapidly throughout the Hubei province. Researchers had confirmed, the virus can spread through
human-to-human transmission [5]. As a person exposed to the virus can take 12 days to grow symptoms [6] and also due to
globalization and easy transportation options the virus spread quickly throughout the world and created a pandemic situation.
As of May 12, 2020, according to worldometer data 4,306,378 people are infected by the coronavirus among them 292,946
people are died by COVID-19 disease [7].
The pandemic of coronavirus caused a crisis in public health accompanying social fear and economic fall in different countries. Due to the fast spread of SARS-CoV-2 in various parts of the world WHO declared it as Public Health Emergency of
International Concern (PHEIC) and the global level assessment of the risk of the impact of COVID-19 is set to very high [8].
Vaccination is the principal long term defense measure from any infectious disease. There is more than 100 vaccines are under
development with some of them in human trial [9]. Nine pharmaceutical giants are racing for to introduce the vaccine for
COVID-19. However, having a vaccine is only the beginning for this kind of large outbreaks. After the introduction of the vaccine main challenge is the distribution of the possibly limited number of future vaccine supplies to the large global population.
Thatâ€™s why the optimization of the vaccination policies before their implementation is necessary to allocate resources in a better
way. The optimal use of vaccines depends on various factors including the structure of the population, vaccine availability, and
transportation availability levels [10].
Several researchers have attempted to develop optimal strategies for different infectious diseases including COVID-19.
Kim et al. applied constrained optimal control for vaccination of influenza [10]. In [11] de Pinho et al. used an optimal
âˆ— Syed Irfan Ali Meerza is a Ph.D student at the Department of Electrical and Computer Engineering, University of Louisville, Louisville,
KY, USA
â€  Seyed M. Karimi is a Assistant Professor at the Department of Health Management and System Sciences, University of Louisville,
Louisville, KY,USA.
â€¡ Bert B. Little is a Professor at the Department of Health Management and System Sciences, University of Louisville, Louisville, KY,USA.
Â§ Jacek M. Zurada is a Professor at the Department of Electrical and Computer Engineering, University of Louisville, Louisville, KY,USA.
Â¶ Tamer Inanc is a Associate Professor at the Department of Electrical and Computer Engineering, University of Louisville, Louisville,
KY,USA.

control approach to SEIR model and introduced l1 cost which is linear with respect to the control variable to the model and
also developed mixed constraints for the model. They limited the number of vaccines available for the policy and solved the
model. De Pinho et al. [12] normalized the SEIR model and tried three different strategies and analyzed their cost. They
also discussed the pros and cons of the normalized SEIR model and compared it with the classical model [13]. Libottea et al.
took the optimal control approach toward the COVID-19 and used mono and multi-objective optimal control to determine the
optimal policy for the vaccine administration in COVID-19 treatment [14]. The mono objective minimizes the infected during
the time horizon while the multi-objective control minimizes the infected individuals and the prescribed vaccine concentration.
They have considered real data from china in their model.
Above mentioned works have focused on the solution of vaccine distribution or scheduling. Only some of them has
considered the vaccine availability during the distribution. Some of them have considered to introduce the medicated individual
in a different group. Almost all of them used hypothetical data for solution. In our work we have considered medicated
individuals in the model as they have different death and recovery rate from the other infected ones. To make the model more
real world worthy we have limited the everyday vaccine availability, as newly introduced vaccine will not be in unlimited supply
and it will be a challenge to provide the vaccine to different locations in a short time. We solved the models for the hypothetical
data used by the work mentioned above to compare the results and also solved the model for real world data of New York State,
USA.
In this paper, we used normalized SEIR model with added medication compartment called SEIRM model and solve for two
different initial data, one is a synthesized data and another is real data for New York State, USA. We have used these data to test
the SEIRM model with and without vaccine limitation. We have used RBF-Galerkin method, recently developed by Hossein
et al. in [15] to find optimal vaccine scheduling. RBF-Galerkin uses Radial Basis Function (RBF) approximation of states and
controls along with Galerkin error projection and collocate them on random nodes to translate the optimal control problem into
a nonlinear programming (NLP) problem foe numerical solution.
We summarize our contributions as follows:
1. We have used a SEIR model with added compartment called the medicated which contains the individuals who are being
medicated for the COVID-19 to better suit the current situation of the pandemic. We have also added limitation on the
supply for vaccine for each day mimic one of the most important hurdle in the distribution.
2. We have used the RBF-Galerkin method to solve the model. RBF-Galerkin method has locality property, which makes
it numerically stable as noise will not influence all the coefficients in the approximation process. We have solved the
model with and without vaccine limitation to compare the results.
3. These models are solved two different datasets, one is the synthesized data used by many researchers to benchmark our
solution then we used a dataset containing real world data of New York state, USA taken on May 12, 2020.
The remainder of this paper is organized as follows. First, we discuss the mathematical models in Section 2. Then, the
optimal control problem related to the mathematical models is presented in Section 3. In Section 4 we have introduced the
RBF-Galerkin method for solving optimal control problems and also the solution of the optimal control problem using the
RBF-Galerkin method. In Section 5, we have solved the optimal vaccination distribution model using real-world data of New
York State,USA. Finally, our conclusions are given in Section 6.

2

Mathematical Model

Researchers have used various compartmental models to represent the evaluation of epidemics and pandemics. These models
are used to understand the epidemic spreading mechanisms and the transmission dynamics in population. These compartmental
models can be divided into two groups i) Population-based models and ii) Agent-based models [16]. Population-based models
can be subdivided into deterministic, stochastic, and discrete-time models. For this research, we have considered one of the
well known compartmental model SEIR. SEIR represents the general interaction among four groups, Susceptible, S (part of
the total population who are not yet infected by the disease pathogen), Exposed, E (part of the population who are exposed
to the infected individual or been infected by the pathogen but havenâ€™t developed any clinical signs), Infected, I (part of the
population who are infected by the pathogen and have visible disease symptoms, they can also infect others) and Recovered, R
(individuals who survived after being infected but is no longer infectious and has developed a natural immunity to the disease
pathogen) [16] [17] [18].
Letâ€™s consider the total population at time t is denoted by N(t). Then the total population will divide into four compartments
susceptible S(t), Exposed E(t), Infected I(t), and Recovered R(t). Consider we have vaccine available then we will provide it
to the susceptible individuals and once they received successful vaccination, they will move to the recovered compartment.
Susceptible individuals can be exposed to the disease pathogen and moved to the exposed compartment and eventually move
to the infected compartment. People can move out of the infected group by recovering from the disease, or by dying due to
infection or other cause. A newly born baby will be added to the susceptible group. Also, people can die due to other causes of
each compartment. Consider death rate due to other reasons is d, the birth rate is b, and death rate due to infection is denoted
by ai . If we denote the rate of vaccination at time t by u(t) then Fig. 1 shows the classical SEIR model and interaction among
the compartments.
For our work, we have considered that spreading of the COVID-19 can be stopped by vaccinating the susceptible and
offering medical care to those who are infected. We also assume that vaccines have efficiency means not everyone getting
the vaccine will not get immune to the virus. The efficiency of the vaccine is denoted by Î·. This means if u(t)S(t) number
of individuals would get vaccine then only Î·u(t)S(t) people would be immune to the virus and would move to the recovered

u(t)S(t)

bN(t)

cS(t)I(t)

S

fE(t)

E

dS(t)

gI(t)

I

dE(t)

R

(a +d)I(t)

dR(t)

i

Figure 1: SEIR Compartmental Model
compartment. Inspired by [12], we have introduced a new compartment in the model denoted by M(t). Individuals who are
infected and getting medical care are members of this group. We denote the rate of getting treatment for the infected individuals
as v(t). Individuals in this compartment who do not die due to the infection or other causes are also considered immune and
moved to the recovered compartment. Considering this new group, the modified model is shown in Fig. 2 and the system
dynamics will be like (1)-(6).
SÌ‡(t) = bN (t) âˆ’ dS(t) âˆ’ cS(t)I(t) âˆ’ Î·u(t)S(t),
(1)
EÌ‡(t) = cS(t)I(t) âˆ’ (f + d)E(t)),
Ë™
I(t) = f E(t) âˆ’ (gi + ai + d)I(t) âˆ’ v(t)I(t),

(2)

RÌ‡(t) = gi I(t) + gm M (T ) âˆ’ dR(t) + u(t)S(t),

(4)

MÌ‡ (t) = âˆ’(gm + am + d)M (t) + v(t)I(t),

(5)

NÌ‡ (t) = (b âˆ’ d)N (t) âˆ’ aI(t),

(6)

(3)

Î·u(t)S(t)

bN(t)

cS(t)I(t)

S
dS(t)

fE(t)

E
dE(t)

giI(t)

I
(a +d)I(t)
i

v(t)I(t)

R
gmM

dR(t)

M
(am+d)M

Figure 2: SEIRM Model
Here S(0)=S0 , E(0)=E0 , I(0)=I0 , R(0)=R0 , M(0)=M0 , N(0)=N0 . Where S0 , E0 , I0 , R0 , M0 , N0 are the non-negative initial
conditions. Observe that N(t) = S(t) + E(t) + I(t) + M(t) + R(t). It is important to note that we considered the size of the
population constant as the time horizon [0, T] is small. Thus the system (1)-(6) covers almost the same population as the initial
population N0 is large and the birth rate could not contribute to the total population in such a short period due to the high death
rate during the pandemic. We have normalized the model as in [12] considering the percentage of the total population to be 1
at instant t which changes the variable to
s(t) =

S(t)
E(t)
I(t)
R(t)
M (t)
, e(t) =
, i(t) =
, R(t) =
, m(t) =
N (t)
N (t)
N (t)
N (t)
N (t)

(7)

which leads us to the following system dynamics
sÌ‡(t) = b âˆ’ ds(t) âˆ’ cs(t)i(t) + (ai i(t) + am m(t))s(t) âˆ’ Î·u(t)s(t),

(8)

3

eÌ‡(t) = cs(t)i(t) âˆ’ (f + d)e(t) + (ai i(t) + am m(t))e(t),

(9)

iÌ‡(t) = f e(t) âˆ’ (g i + ai + d)i(t) + (ai i(t) + am m(t))i(t) âˆ’ v(t)i(t),

(10)

rÌ‡(t) = g i i(t) + g m m(t) âˆ’ dr(t) + (ai i(t) + am m(t))r(t) âˆ’ Î·u(t)s(t),

(11)

mÌ‡(t) = âˆ’(am + g m + d)m(t) + (ai i(t) + am m(t))m(t) + v(t)i(t),

(12)

Optimal Control Problem with Mixed Constraints

In an optimal control problem, the control variable is adjusted to achieve a objective or goal. The actual system can have
several types of equations namely, ordinary differential equations, partial differential equations, discrete equations, etc. In
optimal control definition we denote u(t) as the control and x(t) as the state. The control affects the state function as
x0 (t) = f (t, x(t), u(t))

(13)

where x0 denotes the derivative with respect to time t. Both u(t) and x(t) are responsible for goal achievement. Goal is defined
by a functional called the objective function. The aim is to find the optimal control and corresponding state that achieve the
maximum or minimum of our objective function. Objective function can be represented by as following
Z tf
M aximize or M inimize J(x, u) =
L(t, x(t), u(t))dt
(14)
t0

where L is running cost , ti is the initial time when the control starts and tf is the final time which is either fixed or free
depending on the goal.
According to the model described section 2 we have considered the following optimal control problem with control state
constraints
ï£±
RT
ï£´
ï£´M inimize J 1 (x, u, v) = 0 (Qi(t) + W u(t) + Y v(t))dt
ï£´
ï£´
ï£´
Subject to
ï£´
ï£´
ï£´
ï£´
ï£´
sÌ‡(t) = b âˆ’ ds(t) âˆ’ cs(t)i(t) + (ai i(t) + am m(t))s(t) âˆ’ Î·u(t)s(t)
ï£´
ï£´
ï£´
ï£²eÌ‡(t) = cs(t)i(t) âˆ’ (f + d)e(t) + (a i(t) + a m(t))e(t)
i
m
(15)
A1
ï£´iÌ‡(t) = f e(t) âˆ’ (g i + ai + d)i(t) + (ai i(t) + am m(t))i(t) âˆ’ v(t)i(t)
ï£´
ï£´
ï£´
ï£´
ï£´
ï£´mÌ‡(t) = âˆ’(am + g m + d)m(t) + (ai i(t) + am m(t))m(t) + v(t)i(t)
ï£´
ï£´
ï£´
ï£´
u(t)  [0, 1]
f or a.e. t  [0, T ]
ï£´
ï£´
ï£³
v(t)  [0, 1]
f or a.e. t  [0, T ]
Here Q,W ,Y are constant and called infected, vaccination and treatment weight parameters respectively. They are used to focus
the optimization from the aspect of infection, vaccination or medication. We have eliminated the equation for evaluation of the
percentage recovered r(t) as s(t) + e(t) + i(t) + r(t) = 1 for all time t. From problem A1 it is clear that this controller will
minimize the number of infected individual while using distribution the optimal number of vaccine possible. What if we have
a limited vaccine production or limited logistic support, which confines us to use an almost fixed number of vaccine available.
To represent that we have introduced a mixed control-state constraint of the form
u(t)s(t) â‰¤ V

(16)

where V is the upper bound of the vaccine available at each time instant t. Then the total optimal vaccine scheduling problem
becomes as follow
ï£±
RT
ï£´
ï£´M inimize J2 (x, u, v) = 0 (Qi(t) + W u(t) + Y v(t))dt
ï£´
ï£´
ï£´
ï£´
Subject to
ï£´
ï£´
ï£´
ï£´
ï£´
sÌ‡(t) = b âˆ’ ds(t) âˆ’ cs(t)i(t) + (ai i(t) + am m(t))s(t) âˆ’ Î·u(t)s(t)
ï£´
ï£´
ï£´
ï£´
ï£´
ï£²eÌ‡(t) = cs(t)i(t) âˆ’ (f + d)e(t) + (ai i(t) + am m(t))e(t)
A2 iÌ‡(t) = f e(t) âˆ’ (g i + ai + d)i(t) + (ai i(t) + am m(t))i(t) âˆ’ v(t)i(t)
(17)
ï£´
ï£´
ï£´
mÌ‡(t) = âˆ’(am + g m + d)m(t) + (ai i(t) + am m(t))m(t) + v(t)i(t)
ï£´
ï£´
ï£´
ï£´
ï£´u(t)s(t) â‰¤ V
ï£´
ï£´
ï£´
ï£´
ï£´
u(t)  [0, 1]
f or a.e. t  [0, T ]
ï£´
ï£´
ï£´
ï£³v(t)  [0, 1]
f or a.e. t  [0, T ]

4

RBF-Galerkin Method for Optimal Control Problem

In 1968 Hardy [19] developed Radial Basis Function (RBF) for function approximation. RBF is a real-valued function whose
value depends only on the distance from a fixed point called center point.
Ï†(x, c) = Ï†(kx âˆ’ ck)

(18)

where Ï† is the RBF function and c is the center. Any function that satisfies (18) is called the RBF function. As RBFs
are multivariate functions, it can be applied in any direction [20]. RBF-Galerkin method is based on interpolation of global
RBFs on an arbitrary set of collocation points. A various set of collocation points can be chosen arbitrarily for discretization.
For example, a set of ChebyshevGauss (CG), Chebyshev-Gauss-Lobatto (CGL), Legendre-Gauss (LG), and Legendre-GaussLobatto (LGL) nodes, each could be selected as a set of unequally spaced orthogonal nodes to discretize the problem [21].
Similarly, can be used a set of equally-spaced nodes in the time for discretization. Among the common sets of collocation
points, two most popular choices are sets of CGL and LGL nodes distributed over the interval [-1,1]. The first set minimizes
the max-norm of the interpolation error, while the second one minimizes the L2 -norm of the interpolation error.
According to [22], an approach based on the RBF-Galerkin method is proposed to solve the optimal control problem A1
and A2 . To solve the two optimization problems s(t), e(t), i(t), m(t), u(t), and v(t) are approximated using k global RBF
functions within time horizon [0, T ] as following

s(t) = sR (t) =

k
X

Î±j Ï†(kt âˆ’ tj k) =

j=1

e(t) = eR (t) =

k
X

k
X

Î²j Ï†(kt âˆ’ tj k) =

Î±j Ï†(kt âˆ’ tj k) =

k
X

k
X

k
X

k
X

Î»j Ï†(kt âˆ’ tj k) =

(20)

Î±j Ï†j (t)

(21)

k
X

Î»j Ï†j (t)

(22)

Âµj Ï†j (t)

(23)

Ïƒj Ï†j (t)

(24)

j=1

Âµj Ï†(kt âˆ’ tj k) =

j=1

v(t) = v R (t) =

Î²j Ï†j (t)

k
X

j=1

j=1

u(t) = uR (t) =

(19)

j=1

j=1

m(t) = mR (t) =

Î±j Ï†j (t)

j=1

j=1

i(t) = iR (t) =

k
X

k
X
j=1

Ïƒj Ï†(kt âˆ’ tj k) =

j=1

k
X
j=1

where sR (t), eR (t),iR (t),mR (t),uR (t) and v R (t) denotes the RBF approximation of s(t), e(t),i(t),m(t),u(t) and v(t)
respectively. Ï†j is the RBF basis function and Î±j , Î²j , Î³j , Î»j , Âµj , Ïƒj are RBF weights.The problem is then discretized using
Legendre-Gauss-Lobatto (LGL) nodes. LGL nodes Ï„j , j =1, 2,...,k are orthogonal nodes distributed over the interval [-1,1]
given by Ï„1 = âˆ’1 and Ï„k = 1 for 2 â‰¤ j â‰¤ K âˆ’ 1 are the zeros of PÌ‡Kâˆ’1 , the derivative of the Legendre polynomial of degree
K âˆ’ 1, PKâˆ’1 . The integral cost functions of A1 and A2 are also approximated by the Gauss-Lobatto quadrature as
J1 =

k
T X
(wj (Qi(t) + W u(t) + T v(t)))
2 jâˆ’1

(25)

J2 =

k
T X
(wj (Qs(t) + W u(t) + T v(t)))
2 jâˆ’1

(26)

where wj are LGL weights corresponding to LGL nodes, Ï„j  [âˆ’1, 1], given by
wj =

2
K(K âˆ’ 1)[PKâˆ’1 (Ï„j )]2

where j = 1, 2, ....K

(27)

Then the differential equation in (15) and (17) are converted into algebraic equations using the Gaussian differentiation matrix [23] to translate the original Problem A1 and A2 into Non-Linear Programming (NLP) optimization problem. The NLP
problem has the general form
minimize

f (y)

Subject to

lb â‰¤ g(y) â‰¤ ub

(28)

Here y is the vector of decision variables, g(y) is a set of equality and inequality constraints, and lb and ub denote lowerbound and upper-bound vectors. The NLP problem can then be straightforwardly solved using NLP solvers. For this work,
SNOPT [24], a sparse NLP solver, is used to find the optimum solution.

5

Numerical Results

For the numerical solution, two different initial value datasets have been used. One dataset coincided with those in [25] to
solve problem A1 and A2 initially. Then we have used the data from Worldometer [7] for New York State as the initial values
and constants to solve for vaccination policy. Results are presented in two subsections, 5.1 discusses the results found for the
hypothetical dataset, and 5.2 we have discusses the results for the New York State, USA dataset.

5.1

Results for Benchmark (Synthetic) Data

We have utilized the data presented in [25] to test our models and solver that uses RBF-Galerking method.This allowed to
compare our results with other researchers and to find suitable parameters for the RBF functions specific for the problem A1
and A2 . The initial data are shown in Table 1.

Table 1: Parameters with their clinically approved values and constants as in [25]
Parameter Description
Value
b
natural birth rate
0.525
d
natural death rate
0.5
c
incidence coefficient
0.001
f
exposed to infectious rate
0.5
gi
recovery rate of those infected 0.1
gm
recovery rate of those treated
0.1
ai
infection induced death rate
0.2
am
treatment induced death rate
0.2
Î·
efficiency of vaccine
0.8
S0
initial susceptible population
1000
E0
initial exposed population
100
I0
initial infected population
50
R0
initial recovered population
15
N0
initial population
1165
Q
infected weight parameter
100
W
vaccination weight parameter
30
Y
treatment weight parameter
1
T
number of days
20

We have used the RBF-Galerkin method to turn the optimal control problem into an NLP problem and used the SNOPT [24]
tool in Matlab to solve the NLP problem. We have used 100 nodes grid with step size âˆ†t = T /100 = 0.2. We have considered
the upper bound of available vaccine V = 125 which is 10% of the Susceptible and Exposed Population. Fig. 3 and Fig. 4 show
the results for the problem A1 . In Fig. 3b the optimal vaccination policy is presented which lower the susceptible population to
an acceptable low value (see Fig. 3a) as the susceptible population cannot go to zero. The lowest susceptible population can go
is the birthrate of the total population as the newborn children are considered not immune to the virus. But here the susceptible
population is still higher than the birthrate. Meanwhile, the exposed and infected population also go down (see Fig. 4a and
Fig. 4b). However, as the Susceptible Population does not reduce to the birth rate and the incidence rate c is high, the Exposed
and Infected population havenâ€™t reach zero in the defined time horizon. In this problem we havenâ€™t put any bounds on the
number of available vaccine. Due to the use of higher weight parameter for the vaccination, the solver optimizes the number of
vaccine provided each day, thus the vaccine policy shown in the Fig. 3b starts at zero for time t0 and graphs show the optimal
possible vaccine policy.

Figure 3: Susceptible and Vaccination Trajectory for problem A1

Figure 4: Trajectory of Exposed and Infected Population for problem A1
Fig. 5 and Fig. 6 shows the results for problem A2 . As we have set a limit of 125 vaccines available per day, we have
shown the vaccinated population as numbers rather than percentages. Fig. 5b shows the vaccine distribution. It is noticeable
that the values are always under 125. As this is the optimal policy with an upper bound defined so the number doesnâ€™t start
from zero but from a large value. Here we are not considering the leftover vaccines from the following day in the problem. The
Susceptible Population curve of Fig. 5a is now steeper than before and it reaches the birth rate in 17 days. As the susceptible
population is dropping faster the exposed and infected number also goes down to near zero in the defined time horizon.

Figure 5: Susceptible and Vaccination Trajectory for problem A2

Figure 6: Trajectory of Exposed and Infected Population for problem A2

5.2

Results for New York, USA Data

For real world data we have taken the data for New York State, USA considered as the initial epicenter of COVID-19. Finding
the optimal vaccine schedule in small time span for New York will be a challenging task. The initial data was taken on May 12,
2020, is shown in Table 2. As the values are large, they are taken in percentage to make calculations faster and easier.

Table 2: Parameter Values for New York State, USA
Parameter Description
Value
b
natural birth rate
11.5
d
natural death rate
7.8
c
incidence coefficient
0.11
f
exposed to infectious rate
0.5
gi
recovery rate of those infected 16.84%
gm
recovery rate of those treated
75.45%
ai
infection induced death rate
3%
am
treatment induced death rate
0.5%
Î·
Efficiency of vaccine
0.8
S0
initial susceptible population
97.57%
E0
initial exposed population
0.77%
I0
initial infected population
1.34%
R0
initial recovered population
0.32%
Q
infected weight parameter
100
W
vaccination weight parameter
30
Y
treatment weight parameter
1
T
number of days
20

The Fig. 7 and Fig. 8 show the result for New York when problem A1 is considered. The Susceptible Population curve is
much steeper and reaches near the birth rate value faster. The vaccine distribution curve has peak in the beginning and reaches
a saturation point in 9 days. Due to the early drop in the susceptible curve and lower incident coefficient the percentage of
exposed and infected goes down to almost zero in 8 days (as shown in Fig. 8). As the infected weight parameter Q is high,
when the percentage of Infected individuals decreases the vaccine distribution is also reduced (as shown in Fig. 7).

Figure 7: Susceptible and Vaccination Trajectory for New York using problem A1

Figure 8: Trajectory of Exposed and Infected Population of New York using problem A1

For problem A2 we have used a limit of 15% of Susceptible Population to bound the maximum vaccine distribution. This
gives us the results shown in Fig. 9 10. Limiting the upper bound gives a higher initial distribution of vaccination as in Fig. 9b.
Saturation takes a similar time as in the optimal control formulation A1 . The percentage of Susceptible Population goes down to
the birth rate in 6 days. There is a sudden increase in the vaccine distribution at day 3. This is due to an increase in the infected
population around day 2 (see Fig. 10b). At day 1 there is a drop in infected individuals which leads to a drop in vaccination at
day 2, that makes slop of the susceptible curve flatter than the day 1. Which means less people are getting vaccine and moving
out of the susceptible, in other words more people are getting exposed and eventually getting infected. That makes the infected
curve to have a flat region on day 2.

Figure 9: Susceptible and Vaccination Trajectory for New York using problem A2

Figure 10: Trajectory of Exposed and Infected Population of New York using problem A2
Both the optimal control formulation of optimal vaccine scheduling A1 and A2 aim to reduce the Infected Population while
utilizing the optimal vaccination possible. However, this objective function can could be set up differently. For instance, we
can emphasis to reduce the susceptible rather than the infected population, or we can give more emphasis on medication.

6

Conclusion

Vaccine distribution to the large population is always a challenge. As numerous companies are developing vaccines for the
COVID-19, dynamic vaccine distribution policy will be of high importance when the vaccines will become available. In this
study, we have considered widely accepted infectious disease model and solved it for limited vaccine availability. We have
formulated the scheduling of vaccination as two optimal control problems and then presented numerical solutions with two
different datasets, one with real-world COVID-19 related data for New York.USA. We have used an RBF-Galerkin method for
solving the two optimal control formulations. The formulations presented to reduce the infected population while distributing
the vaccine at optimal rate. As the distribution largely depends on the infected population it can sometimes ignore the population
of other groups. However, the optimal control problems are dynamic and they can be formulated to met any other requirements
needed for efficient distribution.

References
[1] Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, and Jianping Zhao. Clinical features of patients infected with
2019 novel coronavirus in wuhan, china. The Lancet, 395(10223):497506, 2020.
[2] Hongzhou Lu, Charles W Stratton, and Yi-Wei Tang. Outbreak of pneumonia of unknown etiology in wuhan china: the
mystery and the miracle. Journal of Medical Virology, 92(4):401402, 2020.

[3] International committee on taxonomy of viruses (ictv) website. https://talk.ictvonline.org/.
[4] World health organization (who) website.
https://www.who.int/emergencies/diseases/novelcoronavirus-2019/technical-guidance/.
[5] Qui Li, Xuhua Guan, Peng Wu, and Xiaoye Wang. Early transmission dynamics in wuhan, china, of novel coronavirusinfected pneumonia. New England Journal of Medicine, 382(13):1199â€“1207, 2020.
[6] Stephen A Lauer, Kyra H Grantz, Qifang Bi, and Forrest K Jones. The incubation period of coronavirus disease 2019
(covid-19) from publicly reported confirmed cases: Estimation and application. Annals of Internal Medicine, 172(9):577â€“
582, 2020.
[7] Worldometer website. https://www.worldometers.info/coronavirus/.
[8] World health organization (who) website.
https://www.who.int/news-room/detail/30-01-2020statement-on-the-second-meeting-of-the-international-health-regulations-(2005)emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)/.
[9] 9 pharmaceutical companies racing for a covid-19 vaccine.
https://www.forbes.com/sites/
moneyshow/2020/06/16/9-pharmaceutical-companies-racing-for-a-covid-19-vaccine/
#11aecba976ad.
[10] Jungeun Kim, Hee-Dae Kwon, and Jeehyun Lee. Constrained optimal control applied to vaccination for influenza. Computers and Mathematics with Applications, 71(11):2313â€“2329, 2016.
[11] Maria Do Rosario De Pinho, Igor Kornienko, and Helmut Maurer. Optimal control of a seir model with mixed constraints
and l1 cost. In 11th Portuguese Conference on Automatic Control. Springer, 2014.
[12] Maria Do Rosario De Pinho and Filipa Nunes Nogueira. Costs analysis for the application of optimal control to seir
normalized models. International Federation of Automatic Control (IFAC), 21(27):122â€“127, 2018.
[13] Maria Do Rosario De Pinho and Filipa Nunes Nogueira. On application of optimal control to seir normalized models:
Pros and cons. Mathematical Biosciences and Engineering, 14(1):111â€“126, 2016.
[14] Gustavo Barbosa Libotte, Fran Srgio Lobato, Gustavo Mendes Platt, and Antnio Jos da Silva Neto. Determination of an
optimal control strategy for vaccine administration in covid-19 pandemic treatment, 2020.
[15] Hossein Mirinejad and Tamer Inanc. An rbf collocation method for solving optimal control problems. Robotics and
Autonomous Systems, 87, 2016.
[16] Matt J Keeling and Pejman Rohani. Modeling Infectious Diseases in Humans and Animals. Princeton University Press,
2007.
[17] Fred Brauer and Carlos Castillo Chvez. Mathematical Models in Population Biology and Epidemiology. Springer, 2001.
[18] Herbert W. Hethcote.
42(4):599653, 2000.

The mathematics of infectious diseases.

Society for Industrial and Applied Mathematics,

[19] Rolland L. Hardy. Multiquadric equations of topography and other irregular surfaces. Journal of Geophysical Research,
76(8):19051915, 1971.
[20] Martin D. Buhmann. Radial Basis Functions: Theory and Implementations. Cambridge University Press, 2003.
[21] Paul Williams. Hermitelegendregausslobatto direct transcription in trajectory optimization. Journal of Guidance Control
and Dynamics - J GUID CONTROL DYNAM, 32(4):1392â€“1395, 2009.
[22] Hossein Mirinejad and Tamer Inanc. Individualized anemia management using a radial basis function method. In IEEE
Great Lakes Biomedical Conference, GLBC - Proceedings. IEEE, 2015.
[23] Hossein Mirinejad and Tamer Inanc. A radial basis function method for direct trajectory optimization. In American
Control Conference (ACC). IEEE, 2015.
[24] Philip Gill, Walter Murray, and Michael Saunders. Snopt: An sqp algorithm for large-scale constrained optimization.
SIAM Journal on Optimization, 12(4):979â€“1006, 2002.
[25] Rachael Miller Neilan and Suzanne Lenhart. An introduction to optimal control with an application in disease modeling.
DIMACS Series in Discrete Mathematics, 75:6781, 2010.

